Hormonal
GLP-1 receptor agonists lower serum TSH levels in patients with Type 2 Diabetes, particularly those who experience weight loss, without necessarily changing free thyroxine (FT4) levels, suggesting a mechanism involving central nervous system GLP-1 receptors or improved thyroid hormone sensitivity.
If your TSH levels drop while on a GLP-1 medication, it is likely due to your weight loss or improved metabolic sensitivity, not necessarily a thyroid problem. Your doctor will likely check your Free T4 to ensure your thyroid function is normal. This change is generally considered a positive metabolic adaptation rather than a disease state.
exenatide... decreases serum TSH levels in patients who have reduced their body weight... The decrease in TSH levels might also be associated with weight loss alone... The absence of changes in FT4 concentration could also be due to increased tissue sensitivity to thyroid hormones
Why this rating
Multiple studies cited show consistent TSH reduction with weight loss, though the direct causal link to the drug vs. weight loss is nuanced.
Source
GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
Patrycja Kupnicka et al. · Pharmaceuticals · 2024
DOI 10.3390/ph17111470
More from this paper
- Long-term use of GLP-1 receptor agonists (specifically liraglutide, dulaglutide, and exenatide) is associated with an increased risk of thyroid tumors, including C-cell hyperplasia and medullary thyroid carcinoma, primarily through the stimulation of GLP-1 receptors on thyroid C cells leading to calcitonin gene expression and cellular hyperplasia.Moderate
- GLP-1 receptor agonists may increase the risk of acute pancreatitis and pancreatic cancer, although meta-analyses have sometimes excluded this risk, and the evidence remains inconclusive with conflicting study results.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →